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Objective: To describe the clinical application and effect of MicroPulse™ transscleral cyclophotocoagulation
(MP‐TSCPC) in dogs with glaucoma.
Animals studied: Twelve dogs with primary (n = 8) or secondary (n = 4) glaucoma, aged 2‐13 years (mean ±
SD, 7.2 ± 3.8 years).
Procedures: MP‐TSCPC was performed under sedation or general anesthesia. Laser duty cycle was 31.3%,
laser power varied from 2000‐2800 mW, and each hemisphere was treated for 90‐180 seconds. The probe was
applied to each quadrant in a “sweeping motion,” sparing the 3 and 9 o'clock positions.
Results: The number of MP‐TSCPC procedures per eye varied from 1 to 3 (1.4 ± 0.7). Intraocular pressure
(IOP) was controlled (<25 mm>Hg) in 11/12 dogs (92%) within 1‐15 days post‐operatively. The IOP
control at 1 month and the duration between repeated procedures were significantly greater in eyes treated
with high energy laser (2800 mW) compared to 2000‐2500 mW. Long‐term follow‐up (315.3 ± 100.7 days)
showed controlled IOP in 5/12 (42%) and vision retention in 4/8 (50%) dogs. In unsuccessful cases, loss of
IOP control or vision loss occurred within 3‐245 days (109.1 ± 93.7 days) and 28‐261 days (114 ± 101.6
days), respectively, resulting in a salvage procedure in 6 dogs. Complications were as follows: corneal
hypoesthesia (92%), anterior uveitis (67%), post‐operative ocular hypertension (50%), neurotrophic corneal
ulcer (25%), keratoconjunctivitis sicca (8%), and rubeosis iridis (8%).
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to improve the long‐term effect and reduce the complication rate.
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ABSTRACT 
Objective – To describe the clinical application and effect of MicroPulseTM transscleral 
cyclophotocoagulation (MP-TSCPC) in dogs with glaucoma. 
Animals studied – Twelve dogs with primary (n = 8) or secondary (n = 4) glaucoma, aged 2-13 
years (mean ± SD, 7.2 ± 3.8 years). 
Procedures – MP-TSCPC was performed under sedation or general anesthesia. Laser duty cycle 
was 31.3%, laser power varied from 2000-2800 mW, and each hemisphere was treated for 90-
180 seconds. The probe was applied to each quadrant in a ‘sweeping motion’, sparing the 3 and 9 
o’clock positions. 
Results – The number of MP-TSCPC procedures per eye varied from 1-3 (1.4 ± 0.7). Intraocular 
pressure (IOP) was controlled (< 25 mmHg) in 11/12 dogs (92%) within 1-15 days post-
operatively. The IOP control at 1 month and the duration between repeated procedures were 
significantly greater in eyes treated with high energy laser (2800 mW) compared to 2000-2500 
mW. Long-term follow-up (315.3 ± 100.7 days) showed controlled IOP in 5/12 (42%) and vision 
retention in 4/8 (50%) dogs. In unsuccessful cases, loss of IOP control or vision loss occurred 
within 3-245 days (109.1 ± 93.7 days) and 28-261 days (114 ± 101.6 days), respectively, 
resulting in a salvage procedure in 6 dogs. Complications were as follows: corneal hypoesthesia 
(92%), anterior uveitis (67%), post-operative ocular hypertension (50%), neurotrophic corneal 
ulcer (25%), keratoconjunctivitis sicca (8%) and rubeosis iridis (8%).  
Conclusions – MP-TSCPC is a viable tool for managing canine glaucoma, although further 
studies are required to improve the long-term effect and reduce the complication rate. 
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INTRODUCTION 
Glaucoma, a progressive optic neuropathy associated with increased intraocular pressure (IOP), 
is a leading cause of ocular discomfort and irreversible blindness in dogs and other species.[1] 
Medications alone are often insufficient to manage glaucoma long-term, requiring surgical 
intervention to maintain vision and IOP control. Surgical treatment of glaucoma is directed 
toward altering aqueous humor production, drainage, or a combination of both.[1] A common 
surgical treatment for canine glaucoma is transscleral cyclophotocoagulation (TSCPC).[1] 
Traditional TSCPC uses continuous-wave diode laser to destroy the ciliary body pigmented 
epithelium, thereby decreasing aqueous production. Although studies in dogs have shown 
acceptable IOP control with traditional TSCPC, the resulting visual outcome is often poor given 
the high incidence of complications such as corneal ulceration, intraocular inflammation, 
intraocular hemorrhage, cataract formation, retinal detachment, hypotony, and phthisis bulbi.[2-
4] Some of these complications  may be due to the pronounced tissue disruption and collateral 
damage from the diode laser procedure.[2]  
MicroPulseTM transscleral cyclophotocoagulation (MP-TSCPC) offers a safe and effective 
alternative to traditional TSCPC in humans.[5-9] With this system, the laser beam is ‘chopped’ 
into a train of repeated short, microsecond, “on” pulses followed by longer-duration “off” 
intervals. This pulsatile nature allows the surrounding tissue to cool-off between the pulses, 
resulting in minimal collateral damage. Aquino and colleagues randomized 48 human patients to 
receive either MP-TSCPC or traditional TSCPC.[5] At 12 months, 75% of MP-TSCPC and 29% 
of TSCPC patients achieved an IOP lower than 21 mmHg. Furthermore, greater vision-
threatening complications were noted in the traditional TSCPC group, with higher rates of 
prolonged inflammation, prolonged hypotony and phthisis bulbi.[5]  
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The present study describes preliminary results of MP-TSCPC in dogs with glaucoma, detailing 
the impact of the procedure on various outcomes including intraocular pressure control, vision 
retention, number of anti-glaucoma medications post-operatively and complication rate. 
 
MATERIAL AND METHODS 
Animals 
Dogs were recruited from client-owned patients diagnosed with uncontrolled glaucoma by an 
ophthalmology clinician at Iowa State University’s Lloyd Veterinary Medical Center based on 
consistent clinical signs and intraocular pressure (IOP) ≥ 25 mmHg.[1] Patients were excluded if 
glaucoma developed secondary to intraocular neoplasm. The study was approved by the 
Institutional Animal Care and Use Committee of Iowa State University (protocol # 9-16-8364-
K), and all owners signed a consent form. At enrollment, all patients underwent a complete 
ophthalmic examination including slit-lamp biomicroscopy, indirect fundoscopy, Schirmer tear 
test-1 (STT-1), rebound tonometry (TonoVet, Icare Finland Oy, Helsinki, Finland), corneal 
esthesiometry (Cochet-Bonnet esthesiometer, Luneau Ophtalmologie, Chartres, France), and 
fluorescein staining of the ocular surface. 
 
Procedure 
Immobilization was performed with either short general anesthesia (n = 4) or reversible sedation 
(n = 8). While the anesthetic protocol varied for each patient (based on the anesthesiologist’s 
preference), sedation was consistently performed with intravenous dexmedetomidine (3-4 µg/kg; 
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Dexdomitor®, Zoetis, NJ, USA) and methadone (0.5 mg/kg; Mylan Pharmaceuticals Inc., 
Rockford, IL, USA). This sedation protocol achieved adequate immobilization and analgesia for 
the procedure, although one case had to be converted to general anesthesia given the impact of 
the dog’s heavily pigmented bulbar conjunctiva on the laser procedure Each patient was closely 
monitored using the guidelines of the American Animal Hospital Association.[10] The affected 
eye received topical 0.5% proparacaine (Bausch & Lomb, Rochester, NY, USA) followed by 
2.5% hypromellose ophthalmic solution (Gonak, Akorn Inc., Somerset, NJ, USA) to lubricate the 
corneal surface and facilitate probe motion over the bulbar conjunctiva. The laser probe was 
positioned 1 mm posterior to the limbus, thus targeting the laser beam application 4 mm 
posterior to the limbus. Each quadrant was treated with a ‘sweeping motion’, applying laser 
energy uniformly across the sclera 360° except for the 3 and 9 o’clock positions (Fig. 1). The 
duty cycle was set to 31.3% (i.e. 0.5 ms of “on time” and 1.1 ms of “off time”), and the laser 
energy varied from 2000 to 2800 mW. The treatment duration varied from 45 to 90 seconds per 
quadrant, i.e. 90 to 180 seconds per hemisphere (Table 1). Scleral exposure was facilitated by 
fixating the perilimbal bulbar conjunctiva with a micro-alligator clip (1.25”, Gardner Bender, 
Menomonee Falls, WI) first temporally and then nasally to improve visualization of the temporal 
and nasal quadrants, respectively (see supplementary video). At completion of the procedure, 
sedation was reversed with intramuscular atipamezole (Antisedan®, Zoetis, NJ, USA) or 
anesthesia was discontinued, and non-diabetic patients received an intravenous injection of 
dexamethasone (0.15 mg/kg; Dexamethasone-SP, VetOne, Boise, ID, USA). MP-TSCPC was 
repeated in some cases using similar technique, weeks to months following the initial procedure. 
In a single case, the repeated MP-TSCPC procedure was combined with a gonioimplant (VS3 
Ahmed glaucoma valve, New World Medical, Rancho Cucamonga, CA, USA). 
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Post-operative care 
Dogs were hospitalized for 24 hours to better assess the short-term impact of the MicroPulseTM 
laser on the canine eye. During this time, all patients received frequent lubrication (i-Drop Vet 
Plus q2-4h; I-Med Pharma Inc., Quebec, Canada; or Optixcare q2-4h; Aventix, Ontario, Canada), 
topical anti-glaucoma medications (typically dorzolamide-timolol q8-12h; Hi-Tech Pharmacal 
CO., Inc., Amityville, NY, USA; and latanoprost q8-12h; Akorn Inc., Somerset, NJ, USA), and a 
systemic anti-inflammatory (prednisone 0.5 mg/kg PO q12h; Westward Pharmaceuticals Corp., 
Eatontown, NJ, USA; or carprofen 2.2 mg/kg PO q12h in diabetic dogs; Rimadyl®, Pfizer 
Animal Health, New York, NY, USA). Intraocular pressure was assessed at 1h and 2h post-
operatively, then every 2h thereafter until the patient was sent home. If post-operative IOP rose 
above 25 mmHg within 24 hours following surgery, intravenous mannitol (1-2 g/kg) was 
administered slowly over 20 minutes and water was subsequently withheld for 4 hours. The 
owners were instructed to continue the medications described above except for a reduced 
frequency in lubrication (i-Drop Vet Plus or Optixcare q6-8h) for all and the addition of a neuro-
protective medication (memantine, 20 mg PO twice weekly; Dr Reddy’s Laboratories, 
Hyberabad, India) in selected cases (# 10, 11, 12). 
Recheck examinations were performed at approximately 1 week, 1 month, 3 months, 6 months, 
and 12 months post-operatively, with additional visits scheduled in between the aforementioned 
time points depending on the status of each case and the owner’s concerns. At each visit, a 
complete ophthalmic examination was performed as described above. Anti-glaucoma 
medications were adjusted as deemed appropriate by the clinician in charge, and topical 
cyclosporine 1% (compounded in corn-oil) was used if Schirmer tear test-1 was < 15 mm/min 
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along with clinical signs consistent with keratoconjunctivitis sicca. If needed as a salvage 
procedure in blind and painful eyes, a chemical ciliary body ablation (CBA) was performed 
using an intravitreal injection of either 562.5 µg cidofovir alone (Vistide, Gilead Sciences Inc., 
Foster City, CA, USA)[11] or 25 mg gentamicin (VetOne, Boise, ID, USA) combined with 1 mg 
dexamethasone.  
 
Data analysis 
Intraocular pressure was considered ‘controlled’ if the IOP was lower than but not equal to 25 
mmHg, and the eye considered visual if there was a consistent positive menace response, 
regardless of factors that could impair the quality of vision (e.g. keratitis). In each case, time to 
failure in controlling IOP and time to failure in retaining vision were calculated as the average 
between the last visit (in days post-operatively) in which IOP was controlled or vision was 
present, respectively, and the following visit (in days post-operatively) in which IOP was greater 
than 25 mmHg or vision was absent in the treated eye, respectively. For comparison of surgical 
outcomes, the timing of surgical intervention in relation to diagnosis of glaucoma was defined as 
either ‘early intervention’ (≤ 2 weeks) or ‘late intervention’ (≥ 3 weeks). All data is presented as 
mean ± standard deviation and range (minimum-maximum). The Fisher’s exact test was used to 
investigate the percentage of dogs that had controlled IOP at 1 month (i.e. before MP-TSCPC 
had to be repeated in certain cases), comparing laser energies of 2000-2500 mW vs. 2800 mW 
and comparing ‘early intervention’ vs. ‘late intervention’ groups. A student’s t-test was used to 
compare the duration (in days) between repeated procedures when the initial laser power was set 
to either 2000-2500 mW or 2800 mW. The same test was used to compare the number of daily 
anti-glaucoma drops used before MP-TSCPC vs. the last follow-up visit post-surgery. Statistical 
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analysis was performed using SigmaPlot version 13.0 (Systat software Inc., San Jose, CA), and 
values of P < 0.05 were considered statistically significant. 
 
RESULTS 
MicroPulseTM TSCPC was performed in 14 dogs between October 2016 and March 2017 but one 
case was lost to follow-up within 10 days of therapy and one case was secondary to uveal 
melanoma. Thus, data is reported for 12 dogs and is summarized in Table 1. The mean ± SD age 
was 7.2 ± 3.8 years (range: 2-13 years). The cause of glaucoma was either primary (n = 8) or 
secondary (n = 4; 2 post- phacoemulsification, 1 chronic uveitis, 1 lens subluxation), with a 
duration of 77.6 ± 111.7 days (1-360 days) and a baseline intraocular pressure of 56.8 ± 21.9 
mmHg (28-95 mmHg) despite aggressive medical treatment. In some cases, the IOP was reduced 
immediately prior to MP-TSCPC procedure with either intravenous mannitol administration (1-2 
g/kg; cases # 7, 8, 9, 12) or aqueocentesis (case # 10). The laser power and duration of therapy 
are described in Table 1. The mean ± SD (range) number of laser procedures per eye was 1.4 ± 
0.7 (range: 1-3). Most eyes were only treated once (n = 7), while some eyes were treated twice (n 
= 4) and 1 eye was treated three times. The mean ± SD (range) duration between repeated 
procedures was statistically greater (P < 0.001) when the initial procedure power was 2800 mW 
(172 ± 24 days; range 155-189 days) compared to either 2000 or 2500 mW (28.3 ± 5.5 days; 
range 23-34 days). A very subtle ‘pop’ sound was noted in 6/12 dogs (50%), ranging from 1-2 
soft ‘pops’ per hemisphere. The duration of MP-TSCPC procedure in each eye was between 5 
and 10 minutes. Follow-up time ranged from 90-419 days, with mean ± SD of 315.3 ± 100.7 
days. During that time, the number of anti-glaucoma drops used per day in each dog decreased 
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from 5.6 ± 0.8 drops (3-6 drops) when uncontrolled at baseline, to 5.4  ± 2.7 drops (1-11 drops) 
at the last follow-up visit, although the difference was not statistically significant (P = 1.000). 
IOP control – When considering the first procedure performed in each dog, the percentage of 
dogs with IOP < 25 mmHg at 1 month post-operatively was 17% with either 2000 or 2500 mW 
(1/6 dogs) and 100% with 2800 mW (6/6 dogs). The difference between 2000-2500 mW and 
2800 mW was significant (P = 0.015). Given the poor results of the low energy levels, the 
following efficacy data depicts IOPs obtained after repeated procedures with higher energy 
levels.  
IOP decreased below 25 mmHg in 11/12 dogs (92%) within 6.5 ± 5.9 days (1-15 days). IOP 
control at 1 month post-operatively (83%, 10/12 dogs) was noted in 100% (5/5 dogs) and 71% 
(5/7 dogs) of patients with ‘early intervention’ or ‘late intervention’, respectively. This difference 
was not statistically significant (P = 0.205). At the last follow-up visit, 5/12 (42%) had 
controlled IOP with a mean IOP of 17.0 ± 4.9 mmHg (Table 2), while IOP control was lost in the 
other 6 cases within 109.1 ± 93.7 days (3-245 days). Figure 2 depicts an IOP curve over time in a 
representative dog (case #12) that received two MP-TSCPC treatments with 2800 mW for 180 
seconds per hemisphere, with the second procedure 189 days after the first.  
Vision status – Out of 4 dogs that were blind before MP-TSCPC, 3/4 remained non-visual post-
operatively, while one case (patient #5) regained vision and remained sighted at the last visit 
(Day 412). Of dogs that were visual before laser therapy, 4/8 dogs remained sighted throughout 
the duration of the study while 4/8 lost vision within 114 ± 101.6 days (28-261 days). 
Salvage procedures - A CBA was performed in 5 dogs at 130 ± 91.1 days (12-261 days) 
following MP-TSCPC. The procedure was successful in controlling IOP in all cases, although 
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CBA had to be repeated once in one dog. Enucleation was performed in 1 dog (case # 9) at 90 
days post MP-TSCPC. Histopathological evaluation performed at Iowa State University revealed 
goniodysgenesis, pre-iridal fibrovascular membrane, subtle scleral hyalinization yet no 
noticeable damage to the ciliary body. 
Complications - All cases developed conjunctival hyperemia post-operatively, a finding that was 
accounted for as an ‘expected adverse effect’ and not a complication. Conjunctival hyperemia 
was mild to moderate and resolved within 1-2 weeks following surgery. Of note, not a single dog 
developed hyphema, cataract or retinal separation. By decreasing order of frequency, the 
complications of MP-TSCPC were: 
• Corneal hypoesthesia (n = 11, 92%): Central corneal touch threshold was 2.5 ± 1.0 cm (0.5-
4.5 cm) at baseline and decreased to 1.3 ± 0.9 cm (0-3 cm) at 1 week following MP-TSCPC.  
• Anterior uveitis (n = 8, 67%): Mild and transient anterior uveitis (trace to 1+ flare) was noted 
in cases for which laser power was set to 2500 or 2800 mW. In most cases, the inflammation 
resolved within 1-2 weeks.   
• Post-operative ocular hypertension (n = 6, 50%): POH occurred in 6 dogs and in 9/18 laser 
procedures (50%), with a mean ± SD (range) time from laser therapy of 1.8 ± 1.0 hours (1-4 
hours) and an IOP of 40.7 ± 12.7 mmHg (27-69 mmHg). 
• Neurotrophic corneal ulcer (n = 3, 25%): A superficial corneal ulcer developed post-
operatively in 3 cases within the first few weeks post-operatively (day 5 in case #3, day 3 in 
case #4 and day 20 in case #5). All affected dogs were brachycephalic breeds, and the ulcer 
was characterized by an axial location with loose epithelial edges (Fig. 3A) and concurrent 
corneal hypoesthesia (corneal touch threshold = 1.0 cm in all 3 dogs). Despite aggressive 
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therapy with topical antimicrobials, heterologous serum, and temporary tarsorrhaphy (2/3 
cases), the neurotrophic corneal ulcers were slow to heal, taking 53 days in case #3, 120 days 
in case #4, and 16 days in case #5. In case #4, the healing process involved dense granulation 
tissue and perilesional corneal melanosis (Fig. 3B), resulting in chronic pigmentary changes 
(Fig. 3C).  
• Keratoconjunctivitis sicca (n = 1, 8%): In one dog (case #12), the Schirmer tear test-1 value 
decreased from 15 mm/min at baseline to 4 mm/min 43 days following MP-TSCPC, which 
coincided with a reduction in central corneal touch threshold (4.5 cm at baseline, 3.5 cm at 
43 days). Therapy with twice-daily cyclosporine 1% rapidly improved Schirmer values in the 
affected eye (22 mm/min at last visit). 
• Conjunctival burn (n = 1, 8%): A linear conjunctival burn occurred underneath the path of 
the laser probe in one dog that had heavily pigmented bulbar conjunctiva (case #10). In that 
case, the sedation was converted to general anesthesia so that a conjunctival incision could be 
performed to access the scleral tissue with the MicroPulseTM probe. 
• Rubeosis iridis (n = 1, 8%): Multiple fine iridal blood vessels were noted in case #9 at 60 
days post-operatively. Twenty-nine days later (day 89), IOP spiked to 80 mmHg and, 
following enucleation, histopathological evaluation demonstrated the presence of a pre-iridal 
fibrovascular membrane. 
  
DISCUSSION 
The majority of dogs treated with MP-TSCPC (11/12, 92%) initially responded favorably 
to the procedure and maintained IOP < 25 mmHg for 3 months (10/12, 83%), similar to findings 
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by Sapienza and colleagues, who reported IOP control in 81.2% of treated canine eyes at 2 
months post-operatively.[12] Long-term follow up of our dogs (mean 315 days) showed IOP 
control and retention of vision in 42% and 50% of cases, respectively. A similar trend was 
reported in human patients, for whom IOP control was present in 89.5% of cases at 2 months,[7] 
75% at 12 months and 52% at 18 months post-operatively.[5] Of note, our findings likely 
underestimated the potential success rate of MP-TSCPC as the laser energy used in the first few 
dogs was suboptimal (i.e. less than 2800 mW).  The laser energy was initially set to that 
described in human patients (2000 mW).[5, 6] Based on response to therapy (or lack thereof), the 
power was gradually increased from 2000 mW to 2500 mW to 2800 mW. Furthermore, the 
duration of therapy was gradually increased from 90 seconds to 180 seconds per hemisphere, 
consistent with a protocol used in a more recent study in human patients.[9] 
MicroPulseTM TSCPC may be complimentary to other surgical therapies of glaucoma as 
the presumed mechanism of action of this procedure is different. Whereas continuous-wave 
TSCPC is decreasing aqueous humor production by destroying the ciliary body epithelium,[1] 
MP-TSCPC may increase aqueous humor drainage by changing the position of the trabecular 
meshwork and scleral spur (as shown in an ex vivo model of primate eyes)[13], somewhat similar 
to the chronic use of topical pilocarpine, although this claim requires verification in future canine 
studies. Further, MicroPulseTM has several advantages and drawbacks compared to other surgical 
modalities. The strengths of MP-TSCPC include (i) Rapidity of the procedure: The entire 
procedure was generally completed in less than 10 minutes, especially if performed under 
reversible sedation. In fact, sedation combined with an opioid was the preferred immobilization 
method of the authors as sedation provided adequate analgesia and the scleral exposure was not 
negatively affected by anesthesia-induced ventral strabismus; (ii) Rapidity of IOP reduction: IOP 
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decreased below 25 mmHg within 24 hours in 5 dogs - consistent with findings in humans 
patients [5, 6] - and within 6.5 days on average for 11/12 dogs that responded favorably to MP-
TSCPC in the short-term. This rapid IOP-lowering effect may be due to enhanced uveoscleral 
and/or conventional outflow of aqueous humor.[6, 13] (iii) Minimal inflammation: The amount 
of post-operative intraocular inflammation was minimal to non-existent. When present (67% 
cases), the Tyndall effect was graded as trace or 1+ aqueous flare and, similar to reports in 
humans,[6, 9] resolved within the first 2 weeks post-operatively. The minimal inflammation 
induced by the MicroPulseTM technology is particularly attractive when considering a 
combination procedure of TSCPC with an anterior chamber shunt (such as Ahmed gonio-
implant). This combination surgery was completed in a single dog (case # 11) when IOP 
gradually increased ~ 5.5 months after the initial MP-TSCPC, and that dog has remained visual 
with controlled IOP at the last visit (i.e. 6 months following combination surgery).  Further, none 
of the dogs in the present study developed cataract, unlike patients that were treated with 
Nd:YAG TSCPC [14] or continuous-wave diode laser TSCPC;[3, 4] (iv) Effective in 
subalbinotic eyes: Unlike Nd:YAG laser,[14] MP-TSCPC was successfully performed in two 
Siberian Husky dogs that had subalbinotic eyes, one of which maintained vision and controlled 
IOP at the last follow-up visit (304 days).  
The main drawback of MP-TSCPC is the relative short-term effect of the procedure on the eye. 
The need to repeat MP-TSCPC is well documented in the human literature,[5-9] and was also 
noted in the present canine study. Despite an excellent response of dogs #11 and #12 to the initial 
MP-TSCPC procedure, IOP spiked again after 5-6 months, and a repeated MP-TSCPC was 
performed at 155-189 days post-operatively. The timing for repeating MP-TSCPC is likely 
influenced by each individual situation, and warrants further investigation. Another disadvantage 
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of MP-TSCPC is the impact of the procedure on corneal sensitivity, a complication noted at a 
very high frequency (11/12, 92%). The damage to the long ciliary nerves may be more extensive 
with MP-TSCPC compared to continuous-wave TSCPC, as the former uses a ‘sweeping motion’ 
to apply the laser energy uniformly across the sclera 360° (except for the 3 and 9 o’clock 
positions), while the latter only treats selected areas of the sclera. To reduce the risk of 
neurotrophic corneal ulceration, one could consider performing a temporary tarsorrhaphy at the 
completion of MP-TSCPC [4] and/or using peri-operative topical cyclosporine, as this drug has 
been shown to improve corneo-conjunctival sensitivity.[15] Lastly, the lack of significant 
reduction in post-operative anti-glaucoma medications represents another disadvantage of MP-
TSCPC, and the variability in the number of anti-glaucoma medications used post-operatively 
could represent another confounding factor in the procedure’s efficacy reported herein. The 
frequency of anti-glaucoma therapy may decrease in the short-term, [12] but eventually returned 
to near baseline. However, this finding is contrary to studies in human patients and warrants 
verification by future canine studies that employ standardized MP-TSCPC protocols.[5, 6]  
 
The present study is limited by a small sample size and relatively short follow-up time. These 
limitations restricted our ability to assess the longevity of treatment effect (beyond 12-14 
months) or the occurrence of late complications. Further, the potential benefit of memantine for 
neuroprotection and preservation of vision could not be asserted in the present study due to low 
numbers (3/12 dogs), variable confounding factors (e.g. duration of glaucoma and laser 
parameters) and uncertainty about the efficacy of the dosage used. The latter was selected 
empirically based on authors’ experience, although future studies are needed to assess safety and 
efficacy of this drug in canine glaucoma. Nevertheless, our preliminary findings demonstrated 
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that MicroPulseTM is a viable alternative or adjunct to other therapies for managing canine 
glaucoma. The procedure may work best when using high laser parameters (2800 mW, 180 
seconds per hemisphere) and the long-term outcomes may be improved with early intervention 
for uncontrolled glaucoma.  
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Table 1. Details of 13 dogs treated with MP-TSCPC including signalment, etiology and duration of glaucoma prior to MP-TSCPC, pre-operative and 
post-operative status. POH = Postoperative ocular hypertension. N/A = Not applicable. CBA = Ciliary body ablation. * Baseline data reported for the 
last procedure in cases that had repeated MP-TSCPC. ** MP-TSCPC was combined with Ahmed gonio-implant in this repeated procedure. † 
Immediately prior to salvage procedure (when applicable) or at the last-follow up visit.  
Case # Age (years) Breed Sex Cause of glaucoma 
Glaucoma 
duration 
(days) 
Before procedure * Laser 
POH 
(Y/N) 
IOP < 25 
mmHg at 
1 month 
(Y/N) 
Follow-up 
(days) 
Salvage 
procedure  
(days) 
Last follow up  
# Anti-
glaucoma 
drops per 
day 
IOP Vision 
# 
procedures 
(days from 
previous 
laser) 
Laser power 
(mW) / 
Duration per 
hemisphere 
(sec) 
# Anti-
glaucoma 
drops per 
day † 
IOP last 
visit  
(IOP before 
CBA) 
Vision 
1  5 Blue heeler FS 
Secondary 
(phacoemulsification, 
intumescent diabetic 
cataract) 
62 4 29 N 1 2000 / 90 N N 415 CBA (12), cidofovir 4 24 (42) N 
2  12 Australian Sheperd MN Primary 90 6 28 Y 
1 2000 / 90 Y N 
357 CBA (154), cidofovir 6 16 (59) N 2 (34) 2500 / 90 Y Y 
3  11 French Bulldog X FS 
Secondary (chronic 
uveitis) 6 3 72 Y 1 2000 / 180 Y Y 279 
CBA (261), 
cidofovir 6 5 (38) N 
4  6 Shih Tzu X MN Primary 21 6 74 Y 
1 2000 / 180 Y N 
419 N/A 11 24 Y 2 (23) 2500 / 180 N N 
3 (28) 2800 / 180 Y Y 
5  2 Beagle FS Secondary (lens subluxation) 240 6 44 N 
1 2000 / 120 Y N 
412 N/A 3 33 Y 
2 (29) 2500 / 180 Y Y 
6  5 Boston Terrier FS 
Secondary 
(phacoemulsification, 
mature cataract) 
360 6 75 N 1 2500 / 120 N N 342 
CBA (132), 
gentamicin/
dexameth 
6 4 (67) N 
7  3 Beagle X FS Primary 90 4 95 Y 1 2800 / 180 N Y 160 CBA (91), cidofovir 6 2 (30) N 
8 8 Chow Chow FS Primary 42 6 60 N 1 2800 / 180 Y Y 362 N/A 6 19 N 
9  6.5 Siberian Husky MN Primary 10 6 49 Y 1 2800 / 120 N Y 90 
Enucleation 
(90) 6 80 N 
10  3.5 Siberian Husky FS Primary 7 6 35 Y 1 2800 / 180 Y Y 304 N/A 2 11 Y 
11  13 Shiba Inu FS  Primary 1 6 75 Y 
1 2800 / 180 N Y 
335 N/A 1 14 Y 
2 (155)  2800 / 180 ** N Y 
12  7.5 Shiba Inu FS Primary 7 6 54 Y 
1 2800 / 180 N Y 
308 N/A 8 17 Y 
2 (189) 2800 / 180 N Y 
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Table 2. Follow-up information in 12 dogs treated with MP-TSCPC, detailing the mean ± 
standard deviation IOP in the subset of dogs that retained IOP control (< 25 mmHg) at each visit, 
and the time to failure (days) in dogs that lost IOP control between follow-up visits. N/A = Not 
applicable. 
 
 1 month 3 months 6 months Last visit 
% dogs with IOP < 25 mmHg 83% (10/12) 83% (10/12) 50% (6/12) 42% (5/12) 
IOP in controlled cases (mmHg) 16.5 ± 7.7 16.7 ± 6.4 20.5 ± 4.8 17.0 ± 4.9 
Time to failure in uncontrolled 
cases (days) 11.5 ± 12.0 N/A 93.7 ± 39.5 245 
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Figures 
Figure 1. Schematic of a canine eye showing the MicroPulseTM probe placement (positioned 1 
mm posterior to the corneoscleral limbus) and the ‘sweeping motion’ used to treat each scleral 
quadrant separately, sparing the 3 o’clock and 9 o’clock positions.  
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Figure 2. Representative intraocular pressure curve over time in a 7.5 year-old female spayed 
Shiba Inu dog diagnosed with primary glaucoma (case #12). Baseline IOP (54 mmHg) decreased 
to 7 mmHg within 1 day of the initial MP-TSCPC procedure, then remained below 25 mmHg for 
over 6 months. MP-TSCPC was repeated on day 189 post-operatively as IOP spiked to 39 
mmHg. The second MicroPulseTM procedure controlled IOP within 8 days (day 197) and 
maintained IOP below 25 mmHg until the last follow-up visit (day 308). 
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Figure 3. A neurotrophic corneal ulcer developed in case #4 three days following the second 
MP-TSCPC procedure (A). Dense granulation tissue and perilesional corneal melanosis 
developed over the next few weeks (B, day 59). The ulcer healed by day 120 but dense 
melanosis remained in the axial cornea long-term (C, day 215). 
 
 
 
 
 
